诺华制药 NVS 深 沪
等待开盘 11-12 09:30:00 美东时间
159.47
-3.790
-2.32%
华盛通- 最 高160.62
- 今 开159.62
- 成交量 64.84万股
- 最 低 159.21
- 昨 收 163.26
- 总市值 3011.79亿
- 52周最高 167.3788
- 市盈率 静 22.18
- 换手率 0.03%
- 52周最低 123.4188
- 委 比 94.55%
- 总股本 18.89亿
- 历史最高 167.3788
- 量 比 1.24
- 振 幅 0.86%
- 历史最低 3.8803
- 每 手 1
- 风险率 10.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多关键血脂指标降低78%，却未能减少心梗和中风：诺华放弃潜在重磅心血管药物研发
11月7日，瑞士制药巨头诺华（Novartis）宣布，基本放弃旗下实验性心血管药物pelacarsen的开发，此前一项历时七年、涉及8322名患者的III期临床...
11-08 14:41
诺华确认：Zolgensma治疗患者中出现9例肿瘤报告
（来源：药研网） 11月5日，诺华确认，其脊髓性肌萎缩症（SMA）基因疗法 Zolgensma（onasemnogene abeparvovec）自2019年获...
11-06 16:39
$1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today
Novartis (NYSE:NVS) has outperformed the market over the past 5 years by 6.13% on an annualized basis producing an average annual return of 15.55%. Currently, Novartis has a market capitalization of $311.59 billion. Buying $1000 In NVS: If an investor had bought $1000 of NVS stock 5 years ago, it wo...
11-06 07:15
药物受理最新动态：Novartis Pharmaceutical Manufacturing GmbH司库奇尤单抗注射液进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年11月5日，Novartis Pharmaceutical Manufacturing GmbH的司库奇尤单抗...
11-05 19:15
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics reported Q3 2026 financial results and updates, including the Phase 3 ReDiscover-2 trial for 2L breast cancer expected to complete enrollment mid-2027. Updated data from the ReInspire trial for zovegalisib in vascular anomalies will be presented at ASH 2026. Shannon Campbell was appointed to lead commercial preparations. The company announced a new mutant-selective TIE2 inhibitor program targeting vascular anomalies. Cash reser...
11-04 21:05
强生老将，接手诺华中国 BD
（来源：药研网） 近期，诺华全球官网的 Partnering Leadership Team 页面更新，Sharon Chan 以 Head of Corpo...
11-04 17:30
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
MacroGenics, Inc. announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Both bring extensive oncology drug development experience, which will support the company's pipeline advancement and long-term strategic goals. Dr. Kuriakose has over a decade of experience in oncology and metabolic disease drug development, most recently as Chief Medica...
11-03 21:05
Novartis Terminates BioArctic BrainTransporter Collaboration
An update from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. BioArcti...
11-03 05:02
Allarity Announces First Revenue-Generating Laboratory Services Contract
Allarity Therapeutics ( ($ALLR) ) has provided an update. On October 28, 2026, ...
11-02 21:40
Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment
On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an aggregate current liability of $4,900,000, plus interest, due to Novartis (the "Liability"). The Liabili...
11-02 21:06
